Can-Fite Initiated Phase I Clinical Trial With CF102 First Cohort Was Successfully Completed
Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, is making progress in the development of its second pipeline drug, CF102, for the treatment of liver diseases and in particular liver cancer. The first dose cohort of a phase I clinical trial was successfully completed. Initiation of this phase I trial was enabled by a recently approved FDA IND application submitted by the Company.
More: continued here
Filed under: Clinical Trials on February 26th, 2008